Argenica Therapeutics greenlit to launch Phase II trials into stroke treatment
The Australian company developing ARG-007 to treat death of brain cells following a stroke has received the nod to begin Phase II trials.
Arena Healthcare
The Australian company developing ARG-007 to treat death of brain cells following a stroke has received the nod to begin Phase II trials.
